Lilly targets long-acting obesity market in $870 million Camurus deal
US pharma major Eli Lilly (NYSE: LLY) has struck a deal worth up to $870 million with Swedish biotech Camurus (Nasdaq Stockholm: CAMX), securing global rights to apply the latter’s extended-release delivery platform to a set of its own metabolic disease compounds.
The agreement gives Lilly exclusive worldwide access to Camurus’ FluidCrystal technology for up to four proprietary incretin-based drug candidates. These include dual GIP/GLP-1 receptor agonists, triple GIP/glucagon/GLP-1 receptor agonists, and potentially, amylin receptor agonists.
Camurus is set to receive up to $290 million through upfront, development, and regulatory milestones. Another $580 million is tied to sales-based milestones, with additional tiered royalties on global net product sales in the mid-single-digit range.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze